The use of rociverine as premedication for endoscopy of the upper gastro-intestinal tract: a double-blind controlled clinical trial.
The effect of rociverine (10 or 20 mg given intravenously) as premedication in upper gastro-intestinal tract endoscopy was examined and compared to that of hyoscine butylbromide (20 or 40 mg given i.v.) in a double-blind study involving 121 patients. The drugs' effects were assessed on the degree of opening of the pyloric sphincter and the endoscopist's rating of drug performance. The study showed that rociverine did not differ statistically from the reference drug on either count. No adverse effects were noted.
D000328:Adult; D000368:Aged; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000175:diagnosis; D004384:Duodenoscopy / Q000379:methods*; D005260:Female; D005773:Gastroscopy / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D011292:Premedication
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D003509:Cyclohexanecarboxylic Acids; D010276:Parasympatholytics; D002086:Butylscopolammonium Bromide; C021082:rociverine